Unresectable locally advanced pancreatic cancer
Conditions
Interventions
Gemcitabine (800mg/m2) and nab-paclitaxel (100mg/ m2) are planed to be administered on Day 1, 8, 15, respectively concurrent with radiotherapy to 50.4 Gy in 28 fractions fore the treatment of unresect
Sponsors
Nagoya University Pancreatic Tumor Bord
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who were diagnosed to be pancreatic cancer 2) No distant metastasis 3) Diagnosed unresectable locally advanced pancreatic by rresectability defined by NCCN guideline 4) 20 years of age to 75 years of age 5) ECOG performance status score of 0, 1 6) No prior chemotherapy 7) Primary tumor and adjacent lymph nodes can be treated within 10*10 cm radiation field 8) Enough biliary drainage 9) No invasion to digestive tract 10) No synchronic cancer of other organs 11) Enough oral intake 12) Life expectancy at least 3 months 13) Adequate major organs' function
Exclusion criteria
Exclusion criteria: 1) Distant metastasis 2) Allergy to gemcitabine or nab-paclitaxel 3) Invasion to digestive tract 4) Severe allergy to drags 5) Infection 6) Severe cardiovascular disease 7) Severe basal disease 8) Double cancer 9) Peripheral sensory neuropathy or myelopathy 10) ascites or pleural effusion 11) Active digestive tract bleeding 12) Severe diarrhea 13) Fibroid lung 14) History of radiotherapy for abdomen 15) Uncontrolled cancer pain 16) Lung would be included within radiation field 17) Uncontrolled severe mental disease 18) Pregnant 19) Not obtained consent to this trail 20) Not appropriate for the study at the physician's assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year survival rates | — |
Countries
Japan
Contacts
Public ContactSuguru Yamada
Nagoya University Graduate School of Medicine Gastroenterological Surgery
Outcome results
None listed